Advertisement

Journal of Neural Transmission

, Volume 126, Issue 12, pp 1599–1608 | Cite as

High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson’s disease patients

  • Diego Santos-GarcíaEmail author
  • T. de Deus Fonticoba
  • E. Suárez Castro
  • A. Aneiros Díaz
  • J. M. Paz González
  • M. J. Feal Panceiras
  • C. García Sancho
  • S. Jesús
  • P. Mir
  • M. Aguilar
  • P. Pastor
  • J. Hernández Vara
  • O. de Fábregues-Boixar
  • V. Puente
  • A. Crespo Cuevas
  • I. González-Aramburu
  • J. Infante
  • F. Carrillo Padilla
  • M. Pueyo
  • S. Escalante
  • N. Bernardo
  • B. Solano
  • A. Cots Foraster
  • P. Martinez-Martin
  • on behalf of the COPPADIS Study Group
Neurology and Preclinical Neurological Studies - Original Article

Abstract

C-reactive protein (CRP) is a biomarker of systemic inflammation that has been linked to accelerated decline in walking speed in older adults. The aim of the present study was to compare the CRP levels of PD patients with vs patients without freezing of gait (FOG). Patients and controls participating in the COPPADIS-2015 study that performed blood extraction for determining molecular serum biomarkers were included. Patients with FOG were identified as those with a score of 1 or greater on item-3 of the Freezing of Gait Questionnaire (FOG-Q). Immunoassay was used for determining ultrasensitive CRP (US-CRP) level (mg/dL). In the PD group (n = 225; 61.8 ± 9.5 years old, 61.8% males), 32% of the patients presented FOG but none in the control group (n = 65; 60.3 ± 6.1 years old, 56.9% males) (p < 0.0001). Differences in US-CRP level were significant in patients with FOG vs patients without FOG and vs controls (0.31 ± 0.52 vs 0.16 ± 0.21 vs 0.21 ± 0.22; p = 0.04). Significant differences were also observed between patients with vs without FOG (p = 0.001) but not between patients and controls (p = 0.163). US-CRP level was related to FOG (OR = 4.369; 95% CI 1.105–17.275; p = 0.036) along with H&Y (OR = 2.974; 95% CI 1.113–7.943; p = 0.030) and non-motor symptoms burden (NMSS total score; OR = 1.017; 95% CI 1.005–1.029; p = 0.006) after adjusting for age, gender, disease duration, equivalent daily levodopa dose, number of non-antiparkinsonian drugs per day, motor fluctuations, cognition, motor phenotype, and chronic use of anti-inflammatory drugs. The present study suggests that serum US-CRP level is related to FOG in PD patients. Inflammation could be linked to FOG development.

Keywords

C-Reactive protein Freezing Inflammation Gait Parkinson’s disease 

Abbreviations

BDI-II

Beck depression inventory-II

CRP

C-reactive protein

FOG

Freezing of gait

FOG-Q

Freezing of Gait Questionnaire

NMSS

Non-motor Symptoms Scale

NPI

Neuropsychiatric inventory

PD

Parkinson’s disease

PD-CRS

Parkinson’s Disease Cognitive Rating Scale

PDQ-39SI

39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index

PDSS

Parkinson’s Disease Sleep Scale

PIGD

Postural instability gait difficulty

QUIP-RS

Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale

S&E

Schwab & England Activities of Daily Living Scale

UPDRS

Unified Parkinson’s Disease Rating Scale

VAFS

Visual Analog Fatigue Scale

VAS Pain

Visual analog scale pain

Notes

Acknowledgements

Collaborators (COPPADIS STUDY GROUP): Adarmes Astrid D, Almeria M, Alonso Losada MG, Alonso Cánovas A, Alonso Frech F, Álvarez Sauco M, Arnáiz S, Arribas S, Ascunce Vidondo A, Ávila MA, Bejr-Kasem H, Blázquez Estrada M, Botí M, Borrue C, Cabello González C, Cabo López I, Caballol N, Cámara Lorenzo A, Carrillo F, Casas E, Catalán MJ, Clavero P, Cortina Fernández A, Cubo E, Díez-Fairen M, Erro E, Estelrich Peyret E, Fernández Guillán N, Gámez P, Gallego M, García Caldentey J, García Campos C, García Moreno JM, Gastón I, Gómez Garre MP, González Aloy J, González Ardura J, González García B, González Palmás MJ, González Toledo GR, Golpe Díaz A, Grau Solá M, Guardia G, Horta-Barba A, Kulisevsky J, Kurtis M, Labandeira C, Labrador MA, Lacruz F, Lage Castro M, Legarda I, López Ariztegui N, López Díaz LM, López Manzanares L, López Seoane B, Macías Y, Mata M, Martí Andres G, Martí MJ, Martínez Castrillo JC, McAfee D, Meitín MT, Menéndez González M, Méndez del Barrio C, Miranda Santiago J, Morales Casado MI, Moreno Diéguez A, Nogueira V, Novo Amado A, Novo Ponte S, Ordás C, Pagonabarraga J, Pareés I, Pascual-Sedano B, Pérez Fuertes A, Pérez Noguera R, Planellas L, Prats MA, Prieto Jurczynska C, Redondo Rafales N, Rodríguez Méndez L, Rodríguez Pérez AB, Roldán F, Ruíz De Arcos M, Ruíz Martínez J, Sánchez Alonso P, Sánchez-Carpintero M, Sánchez Díez G, Sánchez Rodríguez A, Santacruz P, Segundo Rodríguez JC, Seijo M, Serarols A, Sierra Peña M, Tartari JP, Valero C, Vargas L, Vázquez Gómez R, Vela L, Villanueva C, Vives B, Villar MD.

Author contributions

DSG: conception, organization, and execution of the project; statistical analysis; writing of the first draft of the manuscript; recruitment and/or evaluation of participants. DF: review and critique; recruitment and/or evaluation of participants. ESC: review and critique. AAD: review and critique. JMPG: review and critique. MJFP: review and critique. CGS: review and critique. SJ: review and critique; recruitment and/or evaluation of participants. PM: review and critique; recruitment and/or evaluation of participants. MA: review and critique; recruitment and/or evaluation of participants. PP: review and critique; recruitment and/or evaluation of participants. JHV: review and critique; recruitment and/or evaluation of participants. OFB: review and critique; recruitment and/or evaluation of participants. VP: review and critique; recruitment and/or evaluation of participants. ACC: review and critique; recruitment and/or evaluation of participants. IGA: review and critique; recruitment and/or evaluation of participants. JI: review and critique; recruitment and/or evaluation of participants. FCP: review and critique; recruitment and/or evaluation of participants. MP: review and critique; recruitment and/or evaluation of participants. SE: review and critique; recruitment and/or evaluation of participants. NB: review and critique; recruitment and/or evaluation of participants. BS: review and critique; recruitment and/or evaluation of participants. ACF: review and critique; recruitment and/or evaluation of participants. PMM: review and critique; overall supervision.

Funding

Santos-García D. has received honoraria for educational presentations and/or advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. de Deus Fonticoba T. has received honoraria for educational presentations and advice service by Abbvie. Suárez Castro E: None. Aneiros Díaz A: None. Paz González JM. has received honoraria for educational presentations and/or advice service by UCB Pharma, Lundbeck, KRKA, and Zambon. Feal Panceiras MJ: None. García Sancho C: None. Jesús S. has received honoraria from Abbvie, Bial, Merz, UCB, and Zambon. She holds the competitive contract “Juan Rodés” supported by the Instituto de Salud Carlos III. Also, she has received grants from the Spanish Ministry of Economy and Competitiveness (PI18/01898) as well as the Consejería de Salud de la Junta de Andalucía (PI-0459-2018). Mir P. has received honoraria from Abbvie, Abbott, Allergan, Bial, Merz, UCB, and Zambon. He has received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación). He also received grants from Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, and the Fundación Mutua Madrileña. Aguilar M: UCB and Schwabe with assistance to a Congress; Nutricia with assistance to a Congress and payment of lecture. Pastor P: None. Hernández Vara J: has received travel bursaries and educational grants from Abbvie and has received honoraria for educational presentations from Abbvie, Teva, Bial, Zambon, Italfarmaco, and Sanofi-Genzyme. de Fábregues-Boixar O. has received honoraria for educational presentations and advice service by Bial, Zambon, Abbvie, KRKA, and Teva. Puente V. has served as consultant for Abbvie and Zambon; has received grant/research from Abbvie. Crespo Cuevas A: None. González-Aramburu I: None. Infante J. has received travel bursaries and honoraria for educational presentations from Abbvie and Zambon. Carrillo Padilla F. has received honoraria from Zambon (SEN Congress assistance). Pueyo M. has received honoraria from Zambon for educational presentations and SEN Congress assistance and of Medtronic for course assistance. Escalante S. has received honoraria for educational presentations and advice service by Abbvie, Zambon, and Bial. Bernardo N: None. Solano B. has received honoraria for educational presentations and advice service by UCB, Zambon, Teva, Abbvie, and Bial. Cots Foraster A has received honoraria for educational presentations by UCB and Zambon, Has received financial help to Master courses (Master en Trastornos del Movimiento, Ed Viguera, 2017–2018) from UCB an Zambon. Martinez-Martin P: Honoraria: from Editorial Viguera for lecturing in courses; International Parkinson and Movement Disorder Society for management of the Program on Rating Scales; Air Liquide, Abbvie, and HM Hospitales de Madrid for advice in clinic-epidemiological studies. License fee payments for the King’s Parkinson’s Disease Pain scale.

Compliance with ethical standards

Conflicts of interest

All authors declare that they have no conflict of interest.

Supplementary material

702_2019_2096_MOESM1_ESM.pdf (122 kb)
Supplementary Material 1 (PDF 122 kb)

References

  1. Amboni M, Stocchi F, Abbruzzese G, DEEP Study Group et al (2015) Prevalence and associated features of self-reported freezing of gait in Parkinson disease: the DEEP FOG study. Parkinsonism Relat Disord 21:644–649CrossRefGoogle Scholar
  2. Anand SS, Yusuf S (2010) C-reactive protein is a bystander of cardiovascular disease. Eur Heart J 31:2092–2096CrossRefGoogle Scholar
  3. Brinkley TE, Leng X, Miller ME, Kitzman DW, Pahor M, Berry MJ et al (2009) Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci 64:455–461CrossRefGoogle Scholar
  4. Bruunsgaard H (2005) Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol 78:819–835CrossRefGoogle Scholar
  5. Carvalho DZ, Schönwald SV, Schumacher-Schuh AF et al (2015) Overnight S100B in Parkinson’s disease: a glimpse into sleep-related neuroinflammation. Neurosci Lett 608:57–63CrossRefGoogle Scholar
  6. Cesari M, Penninx BW, Pahor M et al (2004) Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 59:242–248CrossRefGoogle Scholar
  7. Christine CW, Auinger P, Joslin A, Yelpaala Y, Green R, Parkinson Study Group-DATATOP Investigators (2018) Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson’s disease. Mov Disord 33:762–770CrossRefGoogle Scholar
  8. de Farias CC, Maes M, Bonifacio KL et al (2016) Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson’s disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett 617:66–71CrossRefGoogle Scholar
  9. Fasano A, Herman T, Tessitore A, Strafella AP, Bohnen NI (2015) Neuroimaging of freezing of gait. J Parkinsons Dis 5:241–254CrossRefGoogle Scholar
  10. Hassin-Baer S, Cohen OS, Vakil E et al (2011) Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson’s disease? J Neural Transm 118:539–543CrossRefGoogle Scholar
  11. Iansek R, Danoudis M (2016) Freezing of gait in Parkinson’s disease: its pathophysiology and pragmatic approaches to management. Mov Disord Clin Pract 4:290–297CrossRefGoogle Scholar
  12. Juma WM, Lira A, Marzuk A, Marzuk Z, Hakim AM, Thompson CS (2011) C-reactive protein expression in a rodent model of chronic cerebral hypoperfusion. Brain Res 1414:85–93CrossRefGoogle Scholar
  13. Kositsawat J, Barry LC, Kuchel GA (2013) C-reactive protein, vitamin D deficiency, and slow gait speed. J Am Geriatr Soc 61:1574–1579CrossRefGoogle Scholar
  14. Levin J, Bötzel K, Giese A, Vogeser M, Lorenzl S (2010) Elevated levels of methylmalonate and homocysteine in Parkinson’s disease, progressive supranuclear palsy and amyotrophic lateral sclerosis. Dement Geriatr Cogn Disord 29:553–559CrossRefGoogle Scholar
  15. Lindqvist D, Hall S, Surova Y et al (2013) Cerebrospinal fluid inflammatory markers in Parkinson’s disease—associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 33:183–189CrossRefGoogle Scholar
  16. Mancini M, Bloem BR, Horak FB et al (2019) Clinical and methodological challenges for assessing freezing of gait: future perspectives. Mov Disord (epub ahead of print) Google Scholar
  17. Perez-Lloret S, Negre-Pages L, Damier P et al (2014) Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA Neurol 71:884–890CrossRefGoogle Scholar
  18. Perry VH (2004) The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 18:407–413CrossRefGoogle Scholar
  19. Qiu X, Xiao Y, Wu J, Gan L, Huang Y, Wang J (2019) C-reactive protein and risk of parkinson’s disease: a systematic review and meta-analysis. Front Neurol 10:384CrossRefGoogle Scholar
  20. Rees K, Stowe R, Patel S et al (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies. Cochrane Database Syst Rev 9:11Google Scholar
  21. Sanjari Moghaddam H, Valitabar Z, Ashraf-Ganjouei A, Mojtahed Zadeh M, Ghazi Sherbaf F, Aarabi MH (2018) Cerebrospinal fluid C-reactive protein in Parkinson’s disease: associations with motor and non-motor symptoms. Neuromol Med 20:376–385CrossRefGoogle Scholar
  22. Santos García D, Jesús S, Aguilar M, Planellas LL, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Catalán MJ, López Díaz L, Puente V, García Moreno JM, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Carrillo Padilla F, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Menéndez González M, Seijo M, Rúiz Martínez J, Valero C, Kurtis M, de Fábregues-Boixar O, González Ardura J, Prieto Jurczynska C, Martinez-Martin P, Mir P; COPPADIS Study Group (2019) COPPADIS-2015 (COhort of Patient’s with PArkinson’s DIsease in Spain, 2015) An ongoing global Parkinson’s disease Project about disease progression with more than 1,000 subjects included. Results from the baseline evaluation. Eur J Neurol 66:151–158Google Scholar
  23. Santos García D, Suárez Castro E, Expósito I et al (2017) Comorbid conditions associated with Parkinson’s disease: a longitudinal and comparative study with Alzheimer disease and con-trol subjects. J Neurol Sci 373:210–215CrossRefGoogle Scholar
  24. Santos-García D, Mir P, Cubo E, COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson’s DIsease in Spain, 2015) et al (2016) a global–clinical evaluations, serum biomarkers, genetic studies and neuroimaging–prospective, multicenter, non-interventional, long-term study on Parkinson’s disease progression. BMC Neurol 16:26CrossRefGoogle Scholar
  25. Sathe K, Maetzler W, Lang JD et al (2012) S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain 135:3336–3347CrossRefGoogle Scholar
  26. Sawada H, Oeda T, Umemura A et al (2014) Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson’s disease: case-control study. PLoS One 9:e85886CrossRefGoogle Scholar
  27. Sawada H, Oeda T, Umemura A et al (2015) Baseline C-reactive protein levels and life prognosis in Parkinson disease. PLoS One 10:e0134118CrossRefGoogle Scholar
  28. Sousa AC, Zunzunegui MV, Li A, Phillips SP, Guralnik JM, Guerra RO (2016) Association between C-reactive protein and physical performance in older populations: results from the International Mobility in Aging Study (IMIAS). Age Ageing 45:274–280CrossRefGoogle Scholar
  29. Umemura A, Oeda T, Yamamoto K et al (2015) Baseline plasma C-reactive protein concentrations and motor prognosis in Parkinson disease. PLoS One 10:e0136722CrossRefGoogle Scholar
  30. van Kan Abellan G, Rolland Y, Andrieu S et al (2009) Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) task force. J Nutr Health Aging 13:881–889CrossRefGoogle Scholar
  31. Verghese J, Holtzer R, Lipton RB, Wang C (2012) High-sensitivity C-reactive protein and mobility disability in older adults. Age Ageing 41:541–545CrossRefGoogle Scholar
  32. Zhang H, Yin X, Ouyang Z et al (2016) A prospective study of freezing of gait with early Parkinson disease in Chinese patients. Medicine (Baltimore) 95:e4056CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Diego Santos-García
    • 1
    Email author
  • T. de Deus Fonticoba
    • 2
  • E. Suárez Castro
    • 2
  • A. Aneiros Díaz
    • 2
  • J. M. Paz González
    • 1
  • M. J. Feal Panceiras
    • 1
  • C. García Sancho
    • 1
  • S. Jesús
    • 3
    • 4
  • P. Mir
    • 3
    • 4
  • M. Aguilar
    • 5
  • P. Pastor
    • 5
  • J. Hernández Vara
    • 6
  • O. de Fábregues-Boixar
    • 6
  • V. Puente
    • 7
  • A. Crespo Cuevas
    • 7
  • I. González-Aramburu
    • 4
    • 8
  • J. Infante
    • 4
    • 8
  • F. Carrillo Padilla
    • 9
  • M. Pueyo
    • 9
  • S. Escalante
    • 10
  • N. Bernardo
    • 10
  • B. Solano
    • 11
  • A. Cots Foraster
    • 11
  • P. Martinez-Martin
    • 4
    • 12
  • on behalf of the COPPADIS Study Group
  1. 1.Section of NeurologyCHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, HUACA CoruñaSpain
  2. 2.Hospital Arquitecto Marcide y Hospital Naval, Complejo Hospitalario Universitario de Ferrol (CHUF), FerrolA CoruñaSpain
  3. 3.Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Universidad de Sevilla/CSICSevilleSpain
  4. 4.Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
  5. 5.Hospital Universitari Mutua de Terrassa, TerrassaBarcelonaSpain
  6. 6.Hospital Universitario Vall d’HebronBarcelonaSpain
  7. 7.Hospital del MarBarcelonaSpain
  8. 8.Hospital Universitario Marqués de ValdecillaSantanderSpain
  9. 9.Hospital Universitario de Canarias, San Cristóbal de la LagunaSanta Cruz de TenerifeSpain
  10. 10.Hospital de Tortosa Verge de la Cinta (HTVC), TortosaTarragonaSpain
  11. 11.Institut d’Assistència Sanitària (IAS), Instituí Cátala de la SaludGironaSpain
  12. 12.Centro Nacional de Epidemiología, Instituto de Salud Carlos IIIMadridSpain

Personalised recommendations